Pascal Soriot about statement that AstraZeneca will buy Alexion for $39 bln

Pascal Soriot: It is a tremendous opportunity for us to accelerate our development in immunology, getting into a new segment of disease, a new segment of physicians, and patients we haven’t been able to cover so far.
It is a tremendous opportunity for us to accelerate our development in immunology, getting into a new segment of disease, a new segment of physicians, and patients we haven’t been able to cover so far.
Pascal Soriot

Read more:

More about AstraZeneca:

Latest News

This site uses cookies. By continuing to use this website, you agree to our policies regarding the use of cookies.